Constructing a personalized prognostic risk model for colorectal cancer using machine learning and multi-omics approach based on epithelial-mesenchymal transition-related genes
- PMID: 38282145
- DOI: 10.1002/jgm.3660
Constructing a personalized prognostic risk model for colorectal cancer using machine learning and multi-omics approach based on epithelial-mesenchymal transition-related genes
Abstract
The progression and the metastatic potential of colorectal cancer (CRC) are intricately linked to the epithelial-mesenchymal transition (EMT) process. The present study harnesses the power of machine learning combined with multi-omics data to develop a risk stratification model anchored on EMT-associated genes. The aim is to facilitate personalized prognostic assessments in CRC. We utilized publicly accessible gene expression datasets to pinpoint EMT-associated genes, employing a CoxBoost algorithm to sift through these genes for prognostic significance. The resultant model, predicated on gene expression levels, underwent rigorous independent validation across various datasets. Our model demonstrated a robust capacity to segregate CRC patients into distinct high- and low-risk categories, each correlating with markedly different survival probabilities. Notably, the risk score emerged as an independent prognostic indicator for CRC. High-risk patients were characterized by an immunosuppressive tumor milieu and a heightened responsiveness to certain chemotherapeutic agents, underlining the model's potential in steering tailored oncological therapies. Moreover, our research unearthed a putative repressive interaction between the long non-coding RNA PVT1 and the EMT-associated genes TIMP1 and MMP1, offering new insights into the molecular intricacies of CRC. In essence, our research introduces a sophisticated risk model, leveraging machine learning and multi-omics insights, which accurately prognosticates outcomes for CRC patients, paving the way for more individualized and effective oncological treatment paradigms.
Keywords: colorectal cancer; epithelial-mesenchymal transition; machine learning; multi-omics; personalized oncology.
© 2024 John Wiley & Sons Ltd.
References
REFERENCES
-
- Zhang S, Zhang H, Song P, Wang D, Wang Y. Colorectal cancer therapy mediated by nanomedicines. Chem Commun (Camb). 2023;59(30):4423-4435. doi:10.1039/D2CC06212G
-
- Whitrock JN, Hartman SJ, Shah SA. Transplant for colorectal cancer liver metastases. Surgery. 2023;174(1):106-107. doi:10.1016/j.surg.2023.01.005
-
- Ma YS, Li W, Liu Y, Shi Y, Lin QL, Fu D. Targeting colorectal cancer stem cells as an effective treatment for colorectal cancer. Technol Cancer Res Treat. 2020;19:1533033819892261.
-
- Huang X, Liu J, Liu H, et al. A combined epithelial mesenchymal transformation and DNA repair gene panel in colorectal cancer with prognostic and therapeutic implication. Front Oncol. 2020;10:595182. doi:10.3389/fonc.2020.595182
-
- Sun H, Tian A, Zhang J, Liao X, Zhang N. Epithelial-mesenchymal transition induced by MyoD inhibits growth of high metastatic colorectal cancer. Med Hypotheses. 2019;130:109285. doi:10.1016/j.mehy.2019.109285
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
